Role of Fibrocytes in Chronic Obstructive Pulmonary Disease (FIREBROB)

University Hospital of Bordeaux

Status: Completed

Conditions: Chronic Obstructive Pulmonary Disease

Treatments: Procedure: blood sample; Procedure: Clinical and functional evaluation

Study type: Observational

Funder types: Other

Identifiers

NCT01196832

CHUBX 2010/05

Details and patient eligibility

About

Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling.

Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation.

Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.

Enrollment: 115 patients

Sex: All

Ages: 40+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients: diagnostic of Chronic obstructive pulmonary disease (COPD) exacerbation.
• Control group: subjects without any history of lung disease and with normal lung function testing. Subjects will be separated in 2 sub-groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
• Written informed consent

Exclusion criteria

• Subject without any social security or health insurance
• Asthma, lung fibrosis or idiopathic pulmonary hypertension
• Chronic viral infections (hepatitis, HIV)

Trial design

115 participants in 2 patient groups

Chronic obstructive pulmonary disease patients

Description:

COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux. Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis.

Treatment:

Procedure: blood sample

Procedure: Clinical and functional evaluation

Control group

Description:

Subjects without any history of lung disease and with normal lung function testing

Treatment:

Procedure: blood sample